>Marché du diagnostic du cancer du mélanome au Moyen-Orient et en Afrique, par type de produit (instruments, consommables et accessoires, et autres), type de test (test de biomarqueurs, test d'imagerie, biopsie, tests d'hybridation in situ fluorescente (FISH), tests d'hybridation génomique comparative (CGH), tests immunohistochimiques (IHC) et autres), utilisateur final (hôpitaux, laboratoires associés, laboratoires de diagnostic indépendants, centres d'imagerie diagnostique, instituts de recherche sur le cancer et autres), canal de distribution (appel d'offres direct et vente au détail) - Tendances et prévisions de l'industrie 2030.
Analyse et perspectives du marché du diagnostic du cancer du mélanome au Moyen-Orient et en Afrique
La demande croissante de méthodes de test non invasives à l'échelle mondiale a renforcé la demande du marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent fortement sur divers diagnostics plus rapides pendant cette période cruciale. En outre, les initiatives gouvernementales en matière de diagnostic du cancer du mélanome contribuent également à la demande croissante pour le marché du diagnostic du cancer du mélanome.
Les initiatives stratégiques des acteurs du marché en matière de dépenses de santé en hausse offrent des opportunités au marché. Cependant, le manque de professionnels qualifiés et certifiés et le coût élevé des procédures de diagnostic des cancers du mélanome dans les économies émergentes constituent des défis majeurs pour la croissance du marché.
Le marché du diagnostic du cancer du mélanome au Moyen-Orient et en Afrique devrait connaître une croissance du marché au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 5,8 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 237,89 millions USD d'ici 2030.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable jusqu'au 2020-1015) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Par type de produit (instruments, consommables et accessoires, et autres), type de test (test de biomarqueurs, test d'imagerie, biopsie, tests d'hybridation in situ fluorescente (FISH), tests d'hybridation génomique comparative (CGH), tests immunohistochimiques (IHC) et autres), utilisateur final (hôpitaux, laboratoires associés, laboratoires de diagnostic indépendants, centres d'imagerie diagnostique, instituts de recherche sur le cancer et autres), canal de distribution (appel d'offres direct et vente au détail) |
|
Pays couverts |
Afrique du Sud, Égypte, Arabie saoudite, Émirats arabes unis, Oman, Koweït, Qatar, Bahreïn et reste du Moyen-Orient et de l'Afrique |
|
Acteurs du marché couverts |
Nanostring, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agilent Technologies, Inc., QIAGEN, Inivata Ltd, F. Hoffman-La Roche Ltd, Abbott, AMLo Biosciences Limited, Myriad genetics Genetics Inc, Castle Biosciences, DermTech, Michael Diagnostics Ltd, Damae Medical, Skin Analytics, DermLite, DermaSensor, Skyline Dx, Neracare GmbH, VERISKIN INC., Illumina Inc et bioMérieux SA, entre autres |
Définition du marché
Melanoma cancer diagnostics are known as the process of identifying melanoma cancer by studying skin cells and molecules. These melanoma cancer diagnostics are used as a strategy to research, analyse and diagnose certain cells or molecules with the help of various tests performed in the laboratory. It is specially used for the measurement of a specific biomarker or identifying the biomarker in the skin cells. A melanoma cancer diagnosis is used with the aim of providing more efficient testing and faster diagnostics.
Melanoma cancer diagnostics help doctors find out the cancer stages to effectively treat patients at various stages. Furthermore, with the potential for clinical practice, several tests are used to give additional support to boost efficiency in melanoma cancer diagnosis, and the presence of major market players also contributes to the market growth.
Middle East and Africa Melanoma Cancer Diagnostics Market Dynamics
Drivers
-
Rising demand for early melanoma cancer diagnosis
A potentially fatal cancer, melanomas are most frequently found on the skin. The melanoma incidence has increased significantly on a Middle East and Africa scale. The incidence is highest among populations with fair skin and at lower latitudes. It is one of the cancers with the highest average number of years lost to disease per death. Melanoma is a severe personal and economic burden due to increased incidence and mortality. Various high-risk areas have employed preventative measures with varying degrees of success. The genesis of disease and risk factors must be better understood through research initiatives.
-
Rising preference for preventive health check-ups
Preventive health check-ups are preventive actions performed for the initial detection of melanoma cancer disease. Also, a rising preference for preventive health check-ups provides a safeguard against likely exposure to any disease in the future.
Awareness to promote screening is the most important component of melanoma cancer prevention. The check-up is comprised of the identification of cancer and examinations of risk factors to limit loss at an early stage.
Opportunities
-
Increasing healthcare expenditure for melanoma cancer treatment
Growing healthcare infrastructure is an opportunity for the market because if investment in healthcare increases, more people are getting aware of cancer disease and diagnose their health for precaution and cure.
Increasing healthcare expenditure for cancer treatment also helps the patient to take hassle-free advanced treatment for taking better diagnosis and treatment for fast recovery. The spending on health is made up of the combination of out-of-pocket payments (people paying for their own care), government expenditure, and sources, including health insurance and activities by non-governmental organizations. Due to this, increasing healthcare expenditure for cancer treatment is acting as an opportunity for growing the demand of the market.
-
Strategic initiatives by major players
Increasing rates of various types of disease and their severity are widely seen among people globally. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives the market players take. They are taking initiatives such as product launch, collaborations, mergers, acquisitions, and many more over the years and is expected to lead and create more opportunities in the market. For instance, Evonik invested in the short-term growth of its specialty melanoma cancer diagnostics production at its Hanau and Dossenheim locations in Germany, which supplied two of the four melanoma cancer diagnostics for the Pfizer/BioNTech vaccine. According to Spencer, the first batches were delivered to BioNTech in April 2021, months ahead of schedule.
Restraints/Challenges
- Strict regulations and standards for the approval and commercialization of melanoma cancer diagnostic products
The stringent regulations for the commercialization of any product in the market are proving to be a big challenge for the manufacturers of cancer diagnostic products globally that have their own regulations and a different body for the regulatory procedures.
Manufacturers' approval for commercializing product commercializing into the market. Due to this, in the Middle East and Africa region, stringent regulatory policies are expected to hinder the development of the cancer diagnostic market.
The regulatory requirement for approvals of marketing or CE certification and application of laws and regulations could lead to making major changes in business or paying penalties, including the potential loss of business licenses. The resources and costs required to comply with these laws, rules, and regulations are quite high. Different manufacturing challenges for lipid nanoparticle production
Post-COVID-19 Impact on the Middle East and Africa Melanoma Cancer Diagnostics Market
COVID-19 has positively affected the market. As the demand for diagnostics increased, preventive health check-ups were in high demand. Thus COVID-19 affected the melanoma cancer diagnostics market positively.
Recent Development
- In October 2022, Quest Diagnostics Incorporated announced that the company has collaborated with Decode health to get biomarker-based data that can help reduce the time and cost of developing novel diagnostic tests and drug targets for different types of cancer. This will help the company to find innovative paths in the field of R&D and increases the Middle East and Africa presence of the company in the market
- In May 2022, Myriad Genetics, Inc. announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to the company's growing oncology portfolio. This results in growing liquid biopsy space for the precise tumor test
Middle East and Africa Melanoma Cancer Diagnostics Market Scope
The Middle East and Africa melanoma cancer diagnostics market is segmented into product type, test type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables & Accessories
- Others
On the basis of type, the Middle East and Africa melanoma cancer diagnostics market is segmented into instruments, consumables & accessories, and others.
Test Type
- Biopsy
- Imaging test
- Immunohistochemical (IHC) tests
- Biomarkers test
- Fluorescent In Situ Hybridization (FISH) tests
- Comparative Genomic Hybridization (CGH) tests
- Others
Based on test type, the Middle East and Africa melanoma cancer diagnostics market is segmented into biomarkers test, imaging test, biopsy, Fluorescent In Situ Hybridization (FISH) tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and others.
End User
- Hospitals
- Associated labs
- Independent diagnostic laboratories
- Diagnostic imaging centers
- Cancer research institutes
- Others
Based on end user, the Middle East and Africa melanoma cancer diagnostics market is segmented into hospitals, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Based on the distribution channel, the Middle East and Africa melanoma cancer diagnostics market is segmented into direct tender, retail sales, and others.
Melanoma Cancer Diagnostics Market Regional Analysis/Insights
The Middle East and Africa melanoma cancer market is analysed, and market size insights and trends are provided by product type, test type, end user, and distribution channel.
Middle East and Africa melanoma cancer market comprise of the countries South Africa, Egypt, Saudi Arabia, UAE, Oman, Kuwait, Qatar, Bahrain and Rest of Middle East And Africa.
South Africa is expected to dominate the Middle East and Africa melanoma cancer diagnostics market due to the growing demand for quality healthcare and rising demand for non-invasive testing methods are expected to drive the regional market in the forecast period.
The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and Africa brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Melanoma Cancer Diagnostics Market Share Analysis
Le paysage concurrentiel du marché du diagnostic du cancer du mélanome au Moyen-Orient et en Afrique fournit des détails par concurrents. Les détails inclus sont un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence au Moyen-Orient et en Afrique, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché du diagnostic du cancer du mélanome au Moyen-Orient et en Afrique.
Certains des principaux acteurs opérant sur le marché du diagnostic du cancer du mélanome au Moyen-Orient et en Afrique sont Nanostring, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agilent Technologies, Inc, QIAGEN, Inivata Ltd, F. Hoffman-La Roche Ltd, Abbott, AMLo Biosciences Limited, Myriad genetics Genetics Inc, Castle Biosciences, DermTech, Michael Diagnostics Ltd, Damae Medical, Skin Analytics, DermLite, DermaSensor, Skyline Dx, Neracare GmbH, VERISKIN INC., Illumina Inc et bioMerieux SA, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRY INSIGHTS
6.1 DEMOGRAPHIC TRENDS
6.2 KEY PRICING STRATEGIES
6.2.1 PRODUCT INNOVATION
6.2.2 CONSUMER AWARNESS
6.2.3 A VAST NETWORK OF DISTRIBUTION
6.2.4 PARTNERSHIP WITH POPULAR BRANDS BY MAJOR PLAYERS
6.2.5 OTHERS
6.3 KEY PATIENT ENROLLMENT STRATEGIES
6.3.1 IDENTIFICATION OF CUSTOMERS NEED FOR INNOVATIVE DIAGOSTIC PRODUCTS
6.3.2 INCREASING SPECIFIC TACTICS FOR EVERY STEP
6.3.3 EDUCATE AND COMMUNICATE
6.3.4 IMPROVING DIAGNOSIS SEEKING RATE
6.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF MELANOMA CANCER
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.1.3 NOVEL TECHNOLOGIES IN MELANOMA CANCER DIAGNOSTICS
7.1.4 INCREASING AWARENESS REGARDING MELANOMA CANCER
7.2 RESTRAINTS
7.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR MELANOMA CANCERS
7.3 OPPORTUNITIES
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR MELANOMA CANCER TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD MELANOMA CANCER DIAGNOSTICS
7.3.3 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
7.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE
7.4 CHALLENGES
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF MELANOMA CANCER DIAGNOSTIC PRODUCTS
7.4.2 RADIATION RISKS FROM IMAGING TESTS
8 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 IMAGING INSTRUMENTS
8.2.1.1 ULTRASOUND SYSTEMS
8.2.1.2 MRI SYSTEMS
8.2.1.3 CT SYSTEMS
8.2.1.4 OTHERS
8.2.2 BIOPSY INSTRUMENTS
8.2.3 PATHOLOGY-BASED INSTRUMENTS
8.2.3.1 PCR INSTRUMENTS
8.2.3.2 CELL PROCESSORS
8.2.3.3 SLIDE STAINING SYSTEMS
8.2.3.4 TISSUE PROCESSING SYSTEMS
8.2.3.5 OTHER PATHOLOGY-BASED INSTRUMENTS
8.3 CONSUMABLES & ACCESSORIES
8.3.1 KITS
8.3.1.1 PCR KITS
8.3.1.2 NUCLEIC ACID ISOLATION KITS
8.3.1.3 DNA POLYMERASE KITS
8.3.1.4 OTHERS
8.3.2 PROBES
8.3.2.1 Q FISH
8.3.2.2 FLOW FISH
8.3.2.3 OTHERS
8.3.3 REAGENTS
8.3.3.1 ASSAYS
8.3.3.2 BUFFERS
8.3.3.3 PRIMERS
8.3.3.4 OTHERS
8.3.4 OTHER CONSUMABLES
8.4 OTHERS
9 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 ULTRASOUND
9.2.2 MRI
9.2.3 CHEST X-RAY
9.2.4 LYMPHOSCINTIGRAPHY
9.2.5 COMPUTED TOMOGRAPHY (CT) SCAN
9.2.6 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
9.2.7 OTHERS
9.3 BIOPSY
9.3.1 OPTICAL BIOPSY
9.3.2 EXCISIONAL BIOPSY
9.3.3 INCISIONAL BIOPSY
9.3.4 SHAVE BIOPSY
9.3.5 PUNCH BIOPSY
9.3.6 OTHERS
9.4 IMMUNOHISTOCHEMICAL (IHC) TESTS
9.4.1 S100 PROTEIN FAMILY BIOPSY
9.4.2 MELAN-A
9.4.3 PMEL/PMEL17/SILV/GP100
9.4.4 TYROSINASE
9.4.5 MITF
9.4.6 SM5-1
9.4.7 CSPG4/HMW-MAA
9.5 BIOMARKER TEST
9.5.1 BRAF MUTATION TEST
9.5.2 NRAS MUTATION TEST
9.5.3 CKIT TEST
9.5.4 OTHERS
9.6 FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS
9.7 COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS
9.8 OTHERS
10 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 ASSOCIATED LABS
10.4 DIAGNOSTIC IMAGING CENTERS
10.5 INDEPENDENT DIAGNOSTIC LABORATORIES
10.6 CANCER RESEARCH INSTITUTES
10.7 OTHERS
11 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
12 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION
12.1 MIDDLE EAST AND AFRICA
12.1.1 SOUTH AFRICA
12.1.2 EGYPT
12.1.3 SAUDI ARABIA
12.1.4 U.A.E.
12.1.5 OMAN
12.1.6 KUWAIT
12.1.7 QATAR
12.1.8 BAHARAIN
12.1.9 REST OF MIDDLE EAST AND AFRICA
13 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 ABBOTT
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 ILLUMINA, INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BIOMÉRIEUX SA
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 THERMO FISHER SCIENTIFIC INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 F. HOFFMANN-LA ROCHE LTD.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 AGILENT TECHNOLOGIES, INC.
15.6.1 COMPANY PROFILE
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AMLO BIOSCIENCES LIMITED
15.7.1 COMPANY PROFILE
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 CASTLE BIOSCIENCES INC
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 DAMAE MEDICAL
15.9.1 COMPANY PROFILE
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 DERMLITE.
15.10.1 COMPANY PROFILE
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 DERMASENSOR
15.11.1 COMPANY PROFILE
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 DERMTECH
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 INIVATA LTD.
15.13.1 COMPANY PROFILE
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 MICHAEL DIAGNOSTICS LTD
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 MYRIAD GENETICS, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 NANOSTRING
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 NERACARE GMBH
15.17.1 COMPANY PROFILE
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 SKIN ANALYTICS
15.18.1 COMPANY PROFILE
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 SKYLINEDX
15.19.1 COMPANY PROFILE
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENTS
15.2 VERISKIN INC.
15.20.1 COMPANY PROFILE
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENTS
15.21 QIAGEN
15.21.1 COMPANY SNAPSHOT
15.21.2 REVENUE ANALYSIS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
15.22 QUEST DIAGNOSTICS INCORPORATED (2022)
15.22.1 COMPANY SNAPSHOT
15.22.2 REVENUE ANALYSIS
15.22.3 PRODUCT PORTFOLIO
15.22.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
Liste des tableaux
TABLE 1 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA CONSUMERS & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA HOSPITALS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA ASSOCIATED LABS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA DIAGNOSTIC IMAGING CENTERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA OTHERS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA DIRECT TENDER IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA RETAIL SALES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 50 SOUTH AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 SOUTH AFRICA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 52 SOUTH AFRICA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 SOUTH AFRICA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 SOUTH AFRICA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 SOUTH AFRICA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 SOUTH AFRICA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 SOUTH AFRICA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 SOUTH AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 59 SOUTH AFRICA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 60 SOUTH AFRICA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 61 SOUTH AFRICA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 SOUTH AFRICA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 SOUTH AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 64 SOUTH AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 65 EGYPT MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 66 EGYPT INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 67 EGYPT PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 68 EGYPT IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 69 EGYPT CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 70 EGYPT KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 EGYPT REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 EGYPT PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 EGYPT MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 EGYPT BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 EGYPT IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 EGYPT BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 EGYPT IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 EGYPT MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 79 EGYPT MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 80 SAUDI ARABIA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 SAUDI ARABIA INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 82 SAUDI ARABIA PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 83 SAUDI ARABIA IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 84 SAUDI ARABIA CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 85 SAUDI ARABIA KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 SAUDI ARABIA REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 87 SAUDI ARABIA PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 SAUDI ARABIA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 89 SAUDI ARABIA BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 90 SAUDI ARABIA IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 91 SAUDI ARABIA BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 92 SAUDI ARABIA IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 93 SAUDI ARABIA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 94 SAUDI ARABIA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 95 U.A.E MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 U.A.E INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 U.A.E PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 U.A.E IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 U.A.E CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 U.A.E KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 U.A.E REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 U.A.E PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 103 U.A.E MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 U.A.E BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 U.A.E IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 U.A.E BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 107 U.A.E IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 U.A.E MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 109 U.A.E MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 110 OMAN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 111 OMAN INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 112 OMAN PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 113 OMAN IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 114 OMAN CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 115 OMAN KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 116 OMAN REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 OMAN PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 OMAN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 119 OMAN BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 120 OMAN IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 121 OMAN BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 122 OMAN IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 123 OMAN MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 124 OMAN MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 125 KUWAIT MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 126 KUWAIT INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 127 KUWAIT PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 KUWAIT IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 129 KUWAIT CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 130 KUWAIT KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 131 KUWAIT REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 132 KUWAIT PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 133 KUWAIT MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 134 KUWAIT BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 KUWAIT IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 136 KUWAIT BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 137 KUWAIT IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 KUWAIT MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 139 KUWAIT MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 140 QATAR MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 QATAR INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 142 QATAR PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 143 QATAR IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 144 QATAR CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 145 QATAR KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 146 QATAR REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 147 QATAR PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 148 QATAR MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 149 QATAR BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 150 QATAR IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 151 QATAR BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 152 QATAR IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 153 QATAR MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 154 QATAR MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 155 BAHRAIN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 156 BAHRAIN INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 157 BAHRAIN PATHOLOGY-BASED INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 158 BAHRAIN IMAGING INSTRUMENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 159 BAHRAIN CONSUMABLES & ACCESSORIES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 160 BAHRAIN KITS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 BAHRAIN REAGENTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 162 BAHRAIN PROBES IN MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 163 BAHRAIN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 164 BAHRAIN BIOMARKERS TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 165 BAHRAIN IMAGING TEST IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 166 BAHRAIN BIOPSY IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 BAHRAIN IMMUNOHISTOCHEMICAL (IHC) TESTS IN MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 168 BAHRAIN MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 169 BAHRAIN MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 170 REST OF MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE GROWING PREVALENCE OF MELANOMA CANCER AND THE INCREASING AWARENESS REGARDING MELANOMA CANCER ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 ESTIMATED PREVALENCE OF MELANOMA CANCER IN 2020
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET
FIGURE 15 NUMBER OF NEW CASES IN 2018 IN FEMALES OF ALL AGES
FIGURE 16 AGEING EUROPE POPULATION (IN MILLION)
FIGURE 17 ESTIMATED LIFETIME CARE SPENDING
FIGURE 18 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 19 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 23 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 27 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 32 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 35 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 36 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 39 MIDDLE EAST & AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
